Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast versus itraconazole for scalp and facial dandruff in seborrheic dermatitis
IRCT20240527061914N2Phase 3Recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Aug 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in seborrheic dermatitis (SD) comparing Itraconazole control with Apremilast experimental (2 arms). Primary endpoints: Response to treatment and Side effects comparison. Started Aug 2026; status: recruiting.
02
Drugs
apremilastitraconazole
03
Conditions
seborrheic dermatitis (SD)
Beyond the preview
Go deeper on IRCT20240527061914N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240527061914N2.